8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 5, 2026·SEC
CeriBell, Inc.(CBLL)Earnings, Financials & Key Ratios
CBLL•NASDAQ
$19.79
Price updated Jul 6, 2026
AboutCeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.Show more
- Revenue$89M+36.1%
- EBITDA-$52M-33.6%
- Net Income-$53M-32.0%
- EPS (Diluted)-1.46+56.9%
- Gross Margin87.89%+1.4%
- EBITDA Margin-57.85%+1.8%
- Operating Margin-65.57%-8.1%
- Net Margin-59.97%+3.0%
- ROE-30.83%+69.9%
CBLL Price & Volume
CeriBell, Inc. (CBLL) stock price & volume — 10-year historical chart
Loading chart...
Aggressive Commercial Scaling Pressures Liquidity and Margins
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Expanding
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and Burn Rate
Key Thesis Takeaways
- CeriBell is currently prioritizing rapid market penetration in the acute care sector, evidenced by a 29.3% year-over-year revenue growth in 2026Q1, though this strategy has resulted in significant operating losses and a -78.3% operating margin.
- While the company benefits from elite 87.3% gross margins driven by its recurring disposable revenue model, the lack of operating leverage and a shrinking cash balance of $45.3M present substantial execution risks.
- Investors should monitor the company's ability to moderate its $37.7M quarterly SG&A spend to avoid potential liquidity constraints over the next 12 to 18 months.
Verdict Logic
while the 87.3% gross margin profile is attractive, the current $19.4 million quarterly free cash flow burn rate against a $45.3 million cash position warrants a cautious wait-and-see approach regarding operational efficiency.
CBLL Growth Metrics
CeriBell, Inc. (CBLL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years50.9%
TTM33.75%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-35.66%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM38.72%
Return on Capital
10 Years-40.4%
5 Years-40.4%
3 Years-38.19%
Last Year-30.02%
CBLL Recent Earnings
CeriBell, Inc. (CBLL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (57%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.52-33.3%
$0.39
Rev
$26M+1.6%
$26M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.36+16.3%
$0.43
Rev
$25M+3.6%
$24M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.37+14.0%
$0.43
Rev
$23M-5.7%
$24M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.38+5.0%
$0.40
Rev
$21M-2.6%
$22M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.52vs $0.39-33.3% | $26Mvs $26M+1.6% |
| Q1 2026 | Feb 24, 2026 | $0.36vs $0.43+16.3% | $25Mvs $24M+3.6% |
| Q4 2025 | Nov 4, 2025 | $0.37vs $0.43+14.0% | $23Mvs $24M-5.7% |
| Q3 2025 | Aug 5, 2025 | $0.38vs $0.40+5.0% | $21Mvs $22M-2.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for CeriBell, Inc. (CBLL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.79 | $750.89M | -13.55 | 36.09% | -59.97% | -30.83% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — | |
| $84.03 | $4.62B | -18.88 | 10.74% | 7.47% | 9.13% | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — | |
| $139.97 | $4.3B | 36.83 | -17.57% | 11.93% | 9.79% | — | |
| $83.06 | $106.64B | 22.27 | 8.43% | 13.2% | 9.78% | — |
Compare CBLL vs Peers
CeriBell, Inc. (CBLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CBLL SEC Filings & Documents
CeriBell, Inc. (CBLL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CBLL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CBLL Frequently Asked Questions
CeriBell, Inc. (CBLL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is CeriBell, Inc.'s revenue?
CeriBell, Inc. (CBLL) reported $95.1M in revenue for fiscal year 2025. This represents a 267% increase from $25.9M in 2022.
How fast is CeriBell, Inc. growing?
CeriBell, Inc. (CBLL) grew revenue by 36.1% over the past year. This is strong growth.
Is CBLL profitable?
CeriBell, Inc. (CBLL) reported a net loss of $60.4M for fiscal year 2025.
Dividend & Returns
What is CBLL's return on equity?
CeriBell, Inc. (CBLL) has a return on equity (ROE) of -30.8%. Negative ROE indicates the company is unprofitable.
What is CeriBell, Inc.'s free cash flow?
CeriBell, Inc. (CBLL) had negative free cash flow of $49.6M in fiscal year 2025, likely due to heavy capital investments.